1. Scrip
  2. >>Business
  3. >>Financing

Finance Watch: Perlmutter’s Eikon Raises $106m, In-Licenses Pipeline Programs

Start-Up Has Raised Nearly $775m To Date

 
• By Mandy Jackson

Private Company Edition: Former Merck R&D head Roger Perlmutter and his new team have accessed drug candidates in oncology and neurodegenerative diseases from three companies, along with new funding. Also, Carmot raised $150m in series E equity and BenchSci brought in $70m.

Finance Watch Private Company
• Source: Shutterstock

Eikon Therapeutics, Inc. announced the first venture capital mega-round of $100m or more for June, revealing that it raised $106m in the first tranche of a series C funding round on 1 June. The financing news was overshadowed, however, by the company’s disclosure that it in-licensed several preclinical and clinical-stage drug candidates from three different companies, providing some insight into Eikon’s therapeutic focus after three and a half years of mystery despite its significant fundraising to date.

Hayward, CA-based Eikon was founded in late 2019 with plans to use super-resolution microscopy to elucidate the behavior of proteins...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Actithera Raises $75m To Enter Competitive FAP-Targeting Radioligand Field

 
• By Andrew McConaghie

While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.

Venture Funding Plummets In Q2 As Mega-Rounds Falter

 
• By Mandy Jackson

Evaluate’s second quarter data show that VC rounds of $100m or more totaled $2.36bn, down from $5.25bn in Q2 of 2024. Overall, the Q2 total dropped year-over-year to $4.92bn from $7.95bn.

Finance Watch: A Mini-Surge In Follow-On Offerings Follows Positive Updates

 
• By Mandy Jackson

Public Company Edition: A breakthrough designation, data and deals prompted big follow-on public offerings in late June and early July, including $402.5m for Cidara, $250.8m for Kymera and $230m for Dyne. Also, Revolution Medicines accessed up to $2bn from Royalty Pharma.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

More from Business